Could a common Anti-Nausea pill change how chemo works?
NCT ID NCT03514381
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 59 people with soft tissue sarcoma who were getting chemotherapy with doxorubicin and ifosfamide. Researchers wanted to see if adding the anti-nausea drug aprepitant changed the amount of ifosfamide in the blood. Patients had blood samples taken during their first chemo cycle (without aprepitant) and second cycle (with aprepitant). The goal was to understand any drug interaction that could affect treatment safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aprepitant (anti-nausea drug) and ifosfamide (chemotherapy)
- What this could lead to
- If successful, this could help doctors adjust chemotherapy dosing when using aprepitant, potentially reducing side effects.
- What could go wrong
- This is a small, completed Phase 4 study focused on drug levels, not on curing sarcoma. It may not lead to changes in treatment guidelines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Regional Du Cancer de Montpellier (Icm)
Montpellier, 34298, France
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Drug duo takes on rare head and neck tumors
- Blood test may spot hidden sarcoma signals
- Vitamin c boosts radiation for sarcoma? early trial shows promise
- Drug combo aims to shrink Hard-to-Treat sarcomas
- Experimental t cell therapy targets sarcoma in small early trial